Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 9Stomach Neoplasms 1Pancreatic Neoplasms 1Nephrotic Syndrome 1Neoplasm Metastasis 1Kidney Diseases 1Hepatitis B 1Gastrointestinal Diseases 1Familial Mediterranean Fever 1Esophageal Neoplasms 1Colorectal Adenocarcinoma 1Cholangiocarcinoma 1BRAF V600 Colorectal Cancer 1Arthritis, Rheumatoid 1Amyloidosis 1Adenomatous Polyposis Coli 1

Interventions

Oxaliplatin 295Capecitabine 209Fluorouracil 183Cisplatin 172Docetaxel 140S 1 (combination) 135Paclitaxel 128Leucovorin 117Irinotecan 110pembrolizumab 104Trastuzumab 75Nivolumab 59apatinib 57Drug Therapy 52sintilimab 46Surgical Procedures, Operative 45Ramucirumab 40Radiotherapy 40Bevacizumab 37Hyperthermic Intraperitoneal Chemotherapy 34Epirubicin 32titanium silicide 31tislelizumab 31Carboplatin 31Gastrectomy 28Cyclophosphamide 27XELOX 25Tegafur 24Folfox protocol 23Albumin-Bound Paclitaxel 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stomach Neoplasms × Pharmaceutical Preparations × Gastrointestinal × Clear all
NCT07364422 2026-01-23

To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer

Onconic Therapeutics Inc.

Phase 1/2 Not yet recruiting
49 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡